Loading
SG
Singular Genomics Systems, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 18 Sept 2024.
Singular Genomics Systems, Inc.: what insiders have been doing
This page follows insider dealings at Singular Genomics Systems, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. The past year has been quiet: not a single insider filing for Singular Genomics Systems, Inc. The previous disclosure was published on 27 February 2025.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
67
Thresholds
n/a
Buy Volume
€980,231
6 ops. · all time
Sell Volume
€191,777
9 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$688.8k
Gross profit-US$480.4k-70% margin
Net income-US$81.6M-11852.5% margin
Last declaration on 27 February 2025
Declarations67 total
372,000 sharesCommon StockSEC:0001415889-25-005952:0
3,283 sharesCommon StockSEC:0000950170-25-027105:0
26,834 sharesCommon StockSEC:0000950170-25-027099:0
60,000 sharesCommon StockSEC:0000950170-25-027089:0
155,583 sharesCommon StockSEC:0000950170-25-027106:0
9,502 sharesCommon StockSEC:0000950170-25-027107:0
15,000 sharesCommon StockSEC:0000950170-25-027096:0
325 sharesCommon StockSEC:0000950170-25-027112:0
1,907 sharesCommon StockSEC:0000950170-25-021402:0
500 sharesCommon StockSEC:0000950170-25-018142:0
500 sharesCommon StockSEC:0000950170-25-018146:0
250 sharesCommon StockSEC:0000950170-25-018136:0
417 sharesCommon StockSEC:0000950170-25-002411:0
250 sharesCommon StockSEC:0000950170-24-137416:0
486 sharesCommon StockSEC:0000950170-24-137425:0
209 sharesCommon StockSEC:0000950170-24-137421:0
500 sharesCommon StockSEC:0000950170-24-126421:0
250 sharesCommon StockSEC:0000950170-24-126419:0
1,907 sharesCommon StockSEC:0000950170-24-126428:0
500 sharesCommon StockSEC:0000950170-24-126423:0
1,666 sharesCommon StockSEC:0000950170-24-112573:0
50,416 shares@ US$12.74100.0% of flowCommon StockSEC:0001415889-24-023623:0
Canonical exit: 15 Dec 2024 (T+90)
250 sharesCommon StockSEC:0000950170-24-107503:0
209 sharesCommon StockSEC:0000950170-24-107504:0
487 sharesCommon StockSEC:0000950170-24-107502:0
25 of 67 declarations
About Singular Genomics Systems, Inc.
Singular Genomics Systems, Inc. is a U.S.-based life science technology company that was listed on the Nasdaq under the ticker OMIC. The company was incorporated in Delaware in 2016 and built its core operations in La Jolla, California, positioning itself as a precision-sequencing and spatial multiomics platform company rather than a traditional pharma developer. Its public filings describe a business focused on enabling researchers and clinicians through proprietary next-generation sequencing and tissue-based analysis technologies. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1850906/000095017022003570/omic-20211231.htm))
At the center of Singular’s model is its proprietary “Sequencing Engine,” a technology base designed to improve speed, accuracy, flexibility, and throughput. From that foundation, the company developed the G4, a benchtop next-generation sequencer targeted at applications such as oncology, immune profiling, single-cell research, and broader genomics workflows. Singular also advanced a second major platform, originally referred to as PX and later highlighted commercially as the G4X Spatial Sequencer, which combines sequencing with spatial analysis, proteomics, and multiomic readouts from tissue samples. In 2024, the company unveiled the G4X and framed it as a platform for high-throughput in situ RNA sequencing, targeted transcriptomics, and proteomics profiling from FFPE tissue. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1850906/000095017022003570/omic-20211231.htm))
Read moreShow less
From a competitive standpoint, Singular occupied a specialized segment of the genomics tools market, where it faced larger, better-capitalized incumbents but differentiated itself through the promise of a dual-purpose instrument that could support both conventional NGS and spatial biology applications. That strategic combination is important for labs and translational research customers looking to consolidate workflows and improve analytical depth without moving across multiple platforms. The company’s product-led strategy also included consumables and related workflows, which are important for long-term customer stickiness and recurring revenue potential. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1850906/000095017022003570/omic-20211231.htm))
Geographically, Singular’s business was centered in the United States, with headquarters and principal operations in La Jolla, California, and a manufacturing/facilities buildout tied to that site. The company’s commercial communications in 2024 emphasized expanding spatial services and preparing for broader G4X commercialization, signaling a transition from instrument development toward platform adoption and services support. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1850906/000119312521233969/d199258dex991.htm))
A major recent development was the acquisition agreement with Deerfield Management announced on December 23, 2024, at $20.00 per share in cash, followed by completion of the merger on February 21, 2025. As a result, OMIC is no longer trading as an independent Nasdaq-listed security, but its SEC Form 4 insider transaction history remains relevant for investors analyzing management behavior, dilution, and historical capital-markets signals. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1850906/000119312525038756/d923657dex991.htm?utm_source=openai))
